LANGHORNE, Pa.--(BUSINESS WIRE)-- Savara Inc. (SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the pricing of an underwritten public offering of ...
AUSTIN, Texas--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the Company has entered into an exclusive license and collaboration agreement with Grifols ...
Savara has mapped out a simple destiny in pursuit of approval for its lead therapy. Recent interest in and support of Savara is overblown. Single minded focus on its lead therapy allows Savara to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback